Anavasi Diagnostics receives funding from the National Institutes of Health for its rapid COVID-19 test.

The gist: Woodinville, Wash.-based startup Anavasi Diagnostics will advance the commercialization of its rapid COVID-19 test with $14.9 million in funding from the U.S. National Institutes of Health, the company announced Tuesday. The startup also has raised $6 million from individual investors. The product: According to the company, its AscencioDx COVID-19 test system yields results equivalent to gold-standard PCR tests, and more cheaply and rapidly נwithin 30 minutes. The system employs a re-usable detector good for more than 3,000 single-use tests. Ӊtҳ a one and done process thatҳ like having a PCR lab in the palm of your hand,ԅ Read More